Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BAM-002; Cisplatin/glutathione; Glutathione/cisplatin - Novelos Therapeutics; Glutoxim; NOV-002

Latest Information Update: 02 Apr 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BAM
  • Developer BAM; Cellectar Biosciences; Novelos Therapeutics
  • Class Oligopeptides; Platinum complexes
  • Mechanism of Action Immunomodulators; Protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cancer
  • Suspended Breast cancer; Ovarian cancer; Radiation injuries
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 11 Feb 2014 Novelos Therapeutics is now called Cellectar Biosciences
  • 11 Apr 2011 Suspended - Phase-II for Breast cancer in USA (Parenteral)
  • 11 Apr 2011 Suspended - Phase-II for Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top